Discovery Labs to Report 2013 Fourth Quarter Financial Results and Hold Conference Call on Thursday, March 13, 2014

Mar 11, 2014, 08:00 ET from Discovery Laboratories, Inc.

WARRINGTON, Pa., March 11, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO),  a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report fourth quarter 2013 financial results on Thursday, March 13, 2014 before the open of the U.S. financial markets.  The Company will host a conference call and live audio webcast at 10:00 a.m. Eastern Time that same day. During the conference call, Discovery Labs' management will discuss the 2013 fourth quarter financial results along with other business updates.  A question-and-answer session will follow managements' remarks.

To access the conference call and participate in the question-and-answer session, the number for domestic callers is (877) 870-4263 and for international callers (412) 317-0790.  The conference call passcode is 10041838. The conference call replay number is (877) 344-7529 or (412) 317-0088 using the same conference call password listed above.

The live audio webcast of the conference call will be available on the Discovery Labs website at  It is recommended that participants log onto the audio webcast at least 15 minutes prior to the call.   A replay of the audio webcast will be available after the call at the Company's website.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care.  Discovery Labs' technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.  Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy but are currently not treated.

For more information, please visit the Company's website at

SOURCE Discovery Laboratories, Inc.